Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.13, FiscalAI reports.
Kiora Pharmaceuticals Trading Up 3.1%
Shares of NASDAQ:KPRX traded up $0.08 on Friday, reaching $2.64. 23,543 shares of the company were exchanged, compared to its average volume of 22,446. Kiora Pharmaceuticals has a 1-year low of $1.76 and a 1-year high of $3.01. The company has a 50-day moving average of $2.57 and a 200-day moving average of $2.37. The firm has a market cap of $11.70 million, a price-to-earnings ratio of -0.97 and a beta of -0.38.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings upgraded shares of Kiora Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 14th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $10.00.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Investments LP purchased a new stake in shares of Kiora Pharmaceuticals during the 3rd quarter worth approximately $33,000. Renaissance Technologies LLC grew its holdings in Kiora Pharmaceuticals by 71.0% in the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock valued at $42,000 after purchasing an additional 8,800 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Kiora Pharmaceuticals in the third quarter valued at $125,000. Alyeska Investment Group L.P. purchased a new position in shares of Kiora Pharmaceuticals in the fourth quarter valued at $152,000. Finally, DRW Securities LLC raised its stake in shares of Kiora Pharmaceuticals by 199.2% during the 4th quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock worth $217,000 after buying an additional 73,417 shares during the last quarter. 76.97% of the stock is currently owned by institutional investors and hedge funds.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.
The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.
Featured Stories
- Five stocks we like better than Kiora Pharmaceuticals
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
